This open-label trial (n=15) will assess the safety and tolerability of a single sub-anesthetic (0.5 mg/kg) intravenous ketamine treatment in individuals aged 50–90 with mild cognitive impairment and depression (MCI-D).
This open-label pilot study will evaluate safety and tolerability of a single 0.5 mg/kg IV ketamine infusion in older adults with mild cognitive impairment and clinically significant depression (MADRS ≥20).
Participants (n=15) undergo screening and baseline assessments including questionnaires, blood draw, cognitive testing, MRI (non-contrast) and optional EEG, receive one IV ketamine infusion, and are assessed at 1, 2, 3, 7, and 30 days post-infusion.
Primary outcomes are safety and tolerability; secondary and exploratory outcomes include changes in depression and cognition, imaging/connectivity measures, and the influence of amyloid biomarker status on response.
Single dose of IV ketamine administered at the standard dose used for depression treatment (0.5 mg/kg).
Single IV infusion (0.5 mg/kg)